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AFTER THE introduction of cyclosporine for immuno-
suppression l and its combination with steroids/ liver 
transplantation transformed the practice of hepatology 
worldwide.3 In our own program (University of Colorado 
until 1980 and University of Pittsburgh thereafter), the 
yearly number of liver replacements rose to a new high of 30 
in 1981, the second year of the so-called cyclosporine era. By 
1987, the number was 396 and over the first six months of 
1988, the number was 250, projecting to a total in 1988 alone 
of about 500 (Figure 1). 
SURVIVAL 
The improved survival in the cyclosporine era explains the 
avalanche of clinical activity. Whereas only one in three 
patients in the precyclosporine era lived for as long as a year 
postoperatively, survival has more than doubled since then 
(Figure 2). The one- and five-year actuarial survival of our 
1,179 patients treated with cyclosporine before the end of 
1987 with a minimum follow-up of at least seven months is 
73 and 64%, respectively. 
There has been considerable stability of this patient popu-
lation after one year (Figure 2). However, a gradual mortal-
ity has continued after one year and a disproportionate 
contribution to this late fall-off has been from two diseases 
that have a high rate of recurrence, namely cancer and B 
virus hepatitis (Figure 3).4 
PREVENTION OF RECURRENT 8-VIRUS HEPATITIS 
Prevention of the recurrent B-virus carrier state is one of the 
improvements that can be envisioned. A human monoclonal 
antibody directed against HBsAg has been produced (San-
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Fig 1. Liver transplantation by year at the University of 
Colorado (through 1980) and the University of Pittsburgh 
(1981,onward)_ 
doz Corporation, East Hanover, NJ) by fusing peripheral 
blood lymphocytes from an immune adult human male to a 
mouse x human myeloma cell.s The resulting human mono-
clonal HBIgG is 50,000 times more potent than commer-
cially available HBlgG prepared from the blood of immune 
donors. Two patients have been treated with this monoclonal 
HBIgG beginning preoperatively or at the anhepatic phase of 
liver transplantation. Using only a few milligrams of the 
super HIBgG one recipient had reduction of the surface 
antigen titer from 1 :30,000 to equivocally detectable (titers 0 
to 1:8), and the other (Figure 4) has had clearing of the 
surface antigen. The half-life of the human monoclonal IgG 
has been more than three weeks, allowing maintenance of an 
antibody excess with widely spaced injections (Figure 4). 
Although past efforts to treat the carrier state before and 
after transplantation with commercial HBIgG or interferon 
have failed, the monoclonal preparation looks more promis-
ing. 
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Fig 2_ Actuarial survival of orthotopic liver recipients in the 
precyclosporine era (1963-1979) and after the introduction of 
cyclosporlne-steroid therapy In early 1980 (1980-1987). 
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Fig 3. Survival curves of patients who were B-vlrus carriers, 
or whose reasons for transplantation was hepatic malignan-
cy. 
TRANSPLANTATION AND CANCER: ORGAN CLUSTERS 
New strategies may also improve the outlook after hepatic 
replacement for the indication of liver malignancies, using 
the liver as part of an organ cluster. The most extreme 
example has been a multivisceral transplantation of the liver, 
pancreas, stomach, small bowel, and colon. This operation 
was performed in dogs in 19606 and again 27 years later in a 
31/2-year-old child with a short-gut syndrome and hepatic 
failure.' The recipient lived for more than six months, and 
achieved meaningful nutritional function of the hollow vis-
cera. For long periods, the child was liberated nearly com-
pletely from parenteral hyperalimentation. She died from 
complications of Epstein-Barr virus associated lymphoprolif-
erative tumors (B-celllymphomas) in the liver that eventu-
ally caused biliary obstruction and lethal bacterial sepsis. 
There was no rejection in the graft. In addition, there was no 
evidence of graft-versus-host disease (GvHD), possibly 
because the multivisceral donor had been treated with a large 
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Fig 4. Results of treatment of a B-virus carrier with human 
monoclonal HBlgG before and after orthotopic liver transplan-
tation. The surface antigen titers were measured with a 
sandwich technique, using a gamma counter. HepatitiS B 
antigen was eliminated from the blood after administration of 
monoclonal antibody. 
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dose of OKT3, with intense localization in donor lymphoid 
tissue of the mouse immunoglobulin.7 Shaffer and Monaco, 
et al,8 have shown in rat Fl hybrid studies how donor. 
pretreatment with antilymphocyte serum (ALS) can prevent 
GvHD and this objective may have been achieved in our 
human case. 
Multivisceral transplantation is not an all-or-none proce-
dure. Recently, we have provided two patients with pancreas-
liver grafts which in one case included the duodenum and a 
segment of jejunum. The first patient had sclerosing cholan-
gitis with cholangiocarcinoma of the distal common duct. 
The second had a spindle cell sarcoma of the duodenum 
which had metastasized to the liver, but not elsewhere 
(Figure 5). In these patients, most of the colon and all of the 
organs in the upper abdomen (liver, pancreas, stomach, 
duodenum, spleen, and proximal jejunum) were removed. 
Under veno-venous bypass from the superior mesenteric vein 
and from the vena caval bed, the hepatico-pancreatic grafts 
were placed and GI continuity was restored as shown in 
Figure 6. These recipients are well but still with a postopera-
tive follow-up of only a few weeks. 
The use of organ clusters that inciude the liver-pancreas 
axis will undoubtedly be used more frequently. A number of 
tumors which cannot be treated now will become susceptible 
to excisional therapy including those already mentioned as 
well as bile duct cell carcinomas and neuroendocrine tumors 
of the pancreas which metastasize to the liver. 
IMPROVEMENTS OF IMMUNOSUPPRESSION 
Although cyclosporine has been central to the revolution of 
the last decade in transplantation, its principal side effect of 
nephrotoxicity puts a cap on the permissible dosage, and this 
has meant that not enough of the drug can be given to control 
all rejections. As an alternative, polypharmaceutical regi-
mens have been developed based on cyclosporine and ste-
roids2 to which azathioprine or monoclonal ALGs can be 
added in what have been called double, triple, and quadruple 
regimens. By using smaller doses of individual drugs, their 
toxicity usually can be minimized. The other approach is to 
continue to add new and safer agents to our armamentar-
ium. 
A prime contender as a new agent is the immunosuppres-
sive drug, FK506, which was first reported by Ochai, et ai, at 
this meeting two years ago,9 and described most optimisti-
cally by Todo, et ai, of the University of Pittsburgh. IO Much 
of Todo's work has been published, but we will mention some 
unpublished observations as well as follow-ups of seven 
previously reported dogs given orthotopic livers and then 
treated with FK506 on postoperative days four, five, and 
six. 1o In these dogs, no other therapy was given. A remark-
able prolongation of survival was obtained with three of the 
animals living beyond a half year. Two beagle recipients are 
still alive in their eighth month with well tolerated livers from 
mongrel donors (Table 1). It has been difficult in the past to 
achieve this kind of tolerance induction (or quasi-tolerance) 
in outbred large animals with short course treatment or 
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Fig 5. CAT scan In a patient 
with a spindle cell sarcoma 
of the duodenum whose 
liver, pancreas, spleen, total 
stomach, ascending colon 
and transverse colon were 
removed en bloc. The re-
placement organs are shown 
In Figure 6. Note the Involve-
ment by tumor metastases 0 " 
all segments of the liver and 
cavitation of a dominant 
mass In the right lobe. 
single dose therapy, antilymphocyte serum (ALS) being the 
only previous agent that has made this possi ble." 
The most significant new (and unpublished) studies with 
FK506 have been with baboons, using the kidney (rather 
than the liver) model for testing. At first, Todo's results with 
baboons were disappointing, using doses per kg that were 
taken from rat and dog experiments (Groups I·III, Table 2). 
When the doses were increased by 5 to 10 times (G roups IV 
and V, T able 2), nearly universal success was achieved . The 
lack of effect of FK in doses that were extrapola ted fro m ra ts 
and dogs was perplexing but eventually expla inable by 
experiments of Dr Adriana Zeevi (of Pittsburgh) in which 
the allo-reactivity of baboon lymphocytes was quantitated in 
tissue culture after exposure to donor antigens. It required 
Fig 6. Reconstruction after removal of upper abdominal 
organs en bloc Including the liver, total pancreas, spleen, 
colon and all or part of the stomach. The homograft organ 
clusters are shaded. Left-The patient had sclerosing cholan-
gitis and cholanglocarcinoma of the distal duct. Right-The 
patient had spindle cell sarcoma of duodenum with massive 
liver metastases (see Fig 5). 
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almost 10 times more FK506 in the tissue culture medium to 
switch off the mixed lymphocyte reactions than was neces-
sary to suppress rat and dog lymphocyte reactions. Thus, 
there is a major species variability in sensitivity to FK506. 
This can be quantitated with Zeevi's clever in vitro technique 
instead of the trial and error approach of times past. 
FK506 will undoubtedly be tried clinically within a short 
time. The drug is not toxic to baboons as was feared in some 
of the preliminary observations reported at an FK sympo-
sium in Gothenberg a little more than a year ago.' 2 
ORGAN PRESERVATION 
Another reason to project an increased acceptance and wider 
application of liver transplantation is improved preservation. 
Until last autumn, human livers were transplanted with a 
sense of urgency, the outside margin of safety being pretty 
much set at 8 or 10 hours using Collin's solution ll or 
plasma-like infusates.'4 This was drastical.Jy changed by 
Jamieson, Kalayoglu, Belzer, and their associates,'S with the 
so-called University of Wisconsin (UW) solution. Using the 
UW solution for slush preservation, we have reported a lack 
of correlation between the time of preservation out to one 
day , and liver injury as reflected by the longest prothrombin 
time in the first postoperative week. highest SGOT, graft 
survival. or patient surviva1.'6 
When the UW solution was tried more widely , there were 
word-of-mouth reports by others of a syndrome of late 
hepatic failure three or four days after seemingly good 
primary function . This delayed syndrome has been said to be 
characterized by a secondary rise of bilirubin, or a failure of 
the bilirubin to fall to normal in the first place, 
To examine this question . we have now looked at an even 
larger total of 266 liver preservations of livers given to 
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Table 1. "Tolerance" Induction by Acute High Dose Treatment with FK506 
Treatment Post Op 
No Treatment 
One mg I kg FK i.m. 
on days 4. 5. 6 
6 
(BIB) 
24 
(M/B) 
(B/B)-Beagle donor to beagle recipient 
(M I B)-Mongrel donor to beagle recipient 
6 
(M/B) 
28 
(M/B) 
7 
(BIB) 
58 
(BIB) 
patients undergoing primary transplantation. The preserva-
tion time was for an average of 12.1 ± 6.6 (SD) hours (range 
4 to 35) in the UW groups versus 6.0 ± 1.6 (SD) hours 
(range 4 to 9) in 142 comparable restrospective controls in 
which Euro-Collins solution was used. These studies have 
merely confirmed the revolutionary value of the UW solu-
tion. Clearly, preservation for a day, or possibly even longer, 
is safe. There was no evidence of a late injury pattern that 
made the recovery profile of the recipients differ from that in 
the past with Euro-Collins solution. 
SUMMARY 
Liver transplantation has become an extraordinarily valu-
able and useful operation, but one that is not perfect and that 
has not been exploited to anything like its full potential. 
Better immunosuppression may become available soon as 
exemplified by developments with the Japanese drug, 
FK506. Improved preservation with the UW solution is 
Table 2. FK506 for Renal Transplantation 
in Unrelated Baboons 
Dose (mg I kg I day) 
Groups I.M.· P.O·' 
0 0 
II 0.5 2 
III 1.0 6 
IV 2.0 12 
V 2.0 18 
*I.M.: on days 1.2.3 
**P.O.: from day 4, onward 
***Rejected. 
Survival Days 
5,7. 11. 14 
14.18 
7.23,76 
>22.>22,>25.>25,>27 
23***.>78.>76,>77.>77 
Canine OL TX Survival in Days 
7 
(M/B) 
72 
(BIB) 
7 
(M/B) 
193 
(BIB) 
19 
(BIB) 
>232 
(M/B) 
35 
(BIB) 
>233 
(M/B) 
already here. With these advantages, liver transplantation is 
certain to become far more widely used than at any time in 
the past. Examples were cited of innovat.ive approaches using 
liver transplantation for the treatment of hepatic malignan-
cies. 
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